A Multicentre, SAD, and MAD Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IV Treatment of CALY-002 in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
Latest Information Update: 12 Apr 2024
At a glance
- Drugs CALY 002 (Primary)
- Indications Atopic dermatitis; Coeliac disease; Eosinophilic oesophagitis
- Focus Adverse reactions
- Sponsors Calypso Biotech
Most Recent Events
- 08 Apr 2024 Status changed from active, no longer recruiting to completed.
- 09 Feb 2024 Planned End Date changed from 1 Sep 2023 to 1 Apr 2024.
- 09 Feb 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Apr 2024.